SavedAdd your journal

Journals / Tüberküloz ve Toraks / 2012 / Cilt: 60 - Sayı: 4

Yüksek doz lipozomal amfoterisin B ile kür sağlanan çocukluk çağı invaziv mukormikozis

Pediatric invasive mucormycosis cured with high dose liposomal amphotericin B

Derya GÜMÜRDÜLÜ
İbrahim BAYRAM
Atila TANYELİ
Süreyya SOYUPAK
Emine KOCABAŞ
Fatih ERBEY
Pages
375–379
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In medical literature this case is one of the highest doses of lyposomal amphotericin B administered to a pediatric patient.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Amphotericin B remains the mainstay medical treatment of pulmonary mucormycosis.
📊
Key Findings & Data:We described a case of pulmonary mucormycosis, which had been treated with 42.55 g (during to 45 weeks) liposomal amphotericin B.
💡
Conclusion & Impact:In medical literature this case is one of the highest doses of lyposomal amphotericin B administered to a pediatric patient.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Amphotericin B remains the mainstay medical treatment of pulmonary mucormycosis. Optimal dose is not defined. We described a case of pulmonary mucormycosis, which had been treated with 42.55 g (during to 45 weeks) liposomal amphotericin B. In medical literature this case is one of the highest doses of lyposomal amphotericin B administered to a pediatric patient.

Özet

Pulmoner mukormikozis medikal tedavisinin temel dayanağı amfoterisin B olup, optimal doz konusunda henüz bir fikir birliği bulunmamaktadır. Bu yazıda pulmoner mukormikozis gelişen akut lenfblastik lösemili bir olgunun 45 haftalık sürede toplam 42.55 g lipozomal amfoterisin B kullanılarak başarıyla tedavi edildiği sunulmaktadır. Tıbbi literatüre bakıldığında bu olgu çocukluk çağında en yüksek dozda lipozomal amfoterisin Bnin başarıyla kullanıldığı ilk olgudur

🔖

Cite This Article

GÜMÜRDÜLÜ, D., BAYRAM, İ., TANYELİ, A., SOYUPAK, S., KOCABAŞ, E., ERBEY, F. (2022). Yüksek doz lipozomal amfoterisin B ile kür sağlanan çocukluk çağı invaziv mukormikozis. Tüberküloz ve Toraks, Cilt: 60 - Sayı: 4, 375–379. https://ajindex.com/articles/618722

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004; 10 (Suppl 1): 31-47
  2. Eucker J, Sezer O, Graf B, Possinger K. Mucormycoses. Mycoses 2001; 44: 253-60
  3. Nosari A, Oreste P, Montillo M, Carrafiello G, Draisci M, Muti G, et al. Mucormycosis in hematologic malignancies: an emerging fungal infection. Haematologica 2000; 85: 1068-71
  4. Funada H, Matsuda T. Pulmonary mucormycosis in a hematology ward. Intern Mewd 1996; 35: 540-4
  5. Pagano L, Ricci P, Tonso A, Nosari A, Cudillo L, Montillo M, et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto). Br J Haematol 1997; 99: 331-6
  6. Ribes JA, Vonover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13: 236-301
  7. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med 1999; 159: 1301-9
  8. Chopra R. Ambisome in the treatment of fungal infections. The UK experience. J Antimicrob Chemother 2002; 49: 43-7
  9. Richardson M, Ellis M. Clinical and laboratory diagnosis. Hosp Med 2000; 61: 610-4
  10. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994; 57: 1044-50
  11. Donado-Una JR, Diaz-Hellin V, Lopez-Encuentra A, EchaveSustaeta JM. Persistent cavitations in pulmonary mucormycosis after apparently successful amphotericin B. Eur J Cardiothorac Surg 2002; 21: 940-2
  12. Ringden O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991; 28(Suppl B): 73-82
  13. Cagatay AA, Oncü SS, Calangu SS, Yildirmak TT, Ozsüt HH, Eraksoy HH. Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: a case report. BMC Infect Dis 2001; 1: 22
  14. Maury S, Leblanc T, Feuilhade M, Molina JM, Schaison G. Successful treatment of disseminated mucormycosis with liposomal amphotericin B and surgery in a child with leukemia. Clin Infect Dis 1998; 26: 200-2
  15. Mondy KE, Haughey B, Custer PL, Wippold FJ 2nd, Ritchie DJ, Mundy LM. Rhinocerebral mucormycosis in the era of lipidbased amphotericin B: case report and literature review. Pharmacother